PharmAthene, Inc. v. SIGA Technologies, Inc.

BVLaw
Full Text of Court Cases
August 8, 2014

Access the Full Article

This article and its downloads are available with a subscription to any of these products:
It is also available in these products:
Already a subscriber or product owner?  Login
This article is also available for purchase. (15,652 words)   Add to Cart >>
Need help? Contact us:
1-503-479-8200 ext 2 or sales@bvresources.com
2834 Pharmaceutical Preparations
325412 Pharmaceutical Preparation Manufacturing
economic damages & lost profits
lost profits, expert testimony, pharmaceutical, contract, contractual remedy, expectation damages, license agreement
PharmAthene, Inc. v. SIGA Technologies, Inc.
2014 Del. Ch. LEXIS 142
US
State Court
Delaware
Court of Chancery
Jeffrey L. Baliban (plaintiff); Dr. Keith Ugone (defendant)
Parsons

Summary

In a major pharmaceutical case, on remand Delaware Chancery finds plaintiff proved it had a reasonable expectation of profits at the time of breach; court accepts plaintiff expert’s damages model, but orders adjustments, particularly to sales quantity.
PharmAthene, Inc. v. SIGA Technologies, Inc.
PDF, Size: 448 KB

See Also

Chancery’s Reversal on Damages Opinion Bodes Well for Plaintiff

Legal and Court Case Update
November 2014

In a major pharmaceutical case, on remand Delaware Chancery finds plaintiff proved it had a reasonable expectation of profits at the time of breach; court accepts plaintiff expert’s damages model, but orders adjustments, particularly to sales quantity.

This article also appears in:
The Comprehensive Guide to Economic Damages, Seventh Edition
Valuation Cases From the Delaware Court of Chancery Show How to Excel